Association between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected with Human Immunodeficiency Virus: A Systematic Review

Rhew, David C.; Bernal, Myriam; Aguilar, Daniel; Iloeje, Uchenna; Goetz, Matthew Bidwell
October 2003
Clinical Infectious Diseases;10/1/2003, Vol. 37 Issue 7, p959
Academic Journal
Examines the association between protease inhibitor use and increased cardiovascular risk in patients with HIV. Morphological signs of cardiovascular disease; Increase of carotid intima thickness; Increase in the mean low density lipoprotein cholesterol levels.


Related Articles

  • Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection. Yilmaz, Aylin; Jennbacken, Karin; Fogelstrand, Linda // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background: Chronic HIV infection is associated with increased risk of cardiovascular disease caused by atherosclerosis. Oxidized forms of low-density lipoprotein (LDL) are present in atherosclerotic lesions and constitute major epitopes for natural antibodies. IgM has been shown to be...

  • Genetic Determinants of Risk Factors for Cardiovascular Disease in a Population from Rural Brazil. Velásquez-Meléndez, Gustavo; Parra, Flavia C.; Gazzinelli, Andrea; Williams-Blangero, Sarah; Correa-Oliveira, Rodrigo // Human Biology;Apr2007, Vol. 79 Issue 2, p179 

    We investigate the heritability of and pleiotropic relationships among triglycerides and cholesterol lipoproteins that have long been considered traditional risk factors for cardiovascular disease. Quantitative lipid and lipoprotein phenotypes were determined for a cross-sectional sample of a...

  • Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Yoshida, Hiroshi; Kurosawa, Hideo; Hirowatari, Yuji; Ogura, Yutaka; Ikewaki, Katsunori; Abe, Ikuro; Saikawa, Shinichi; Domitsu, Kenichi; Ito, Kumie; Yanai, Hidekatsu; Tada, Norio // Lipids in Health & Disease;2008, Vol. 7, Special section p1 

    Background: Increased serum remnant lipoproteins are supposed to predict cardiovascular disease in addition to increased LDL. A new homogenous assay for remnant lipoprotein-cholesterol (RemL-C) has been developed as an alternative to remnant-like particle-cholesterol (RLP-C), an immunoseparation...

  • Cardiovascular disease: Hormone mimic reduces cholesterol. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Mar2008, Vol. 7 Issue 3, p203 

    The article discusses the study "The thyroid hormone mimetic compound KB2115 lower plasma LDL cholesterol and simulates bile acid synthesis without cardiac effects in humans," by Baxter and colleagues. The researchers presented the first clinical data for KB2115 (epirome), a novel mimetic of...

  • Lipid measures for prediction of incident cardiovascular disease in diabetic and nondiabetic adults: results of the 8.6 years follow-up of a population based cohort study. Tohidi, Maryam; Hatami, Masumeh; Hadaegh, Farzad; Safarkhani, Maryam; Harati, Hadi; Azizi, Fereidoun // Lipids in Health & Disease;2010, Vol. 9, p6 

    Background: Diabetes is a strong risk factor for cardiovascular disease (CVD).The relative role of various lipid measures in determining CVD risk in diabetic patients is still a subject of debate. We aimed to compare performance of different lipid measures as predictors of CVD using...

  • CARDIOPROTECTIVE EFFECTS OF PHYTOSTEROLS. Dhankhar, Jyotika // International Journal of Pharmaceutical Sciences & Research;Feb2013, Vol. 4 Issue 2, p589 

    Foods and nutrients play a vital role in normal functioning of the body. They are helpful in maintaining the health of the individual and in reducing the risk of various diseases. Worldwide acceptance of this fact formed a recognition link between "nutrition" and "health" and the concept of...

  • NICE raises the bar with pew lipid targets of 4 and 2. Cressey, Daniel // Pulse;6/28/2007, Vol. 67 Issue 25, p2 

    The article reports on the provisions of the draft guidance of the National Institute of Health and Clinical Excellence (NICE) on lipid modification in Great Britain. The guidance increases the bar on secondary prevention of cardiovascular diseases by asking general practitioners (GP) to...

  • Lipoprotein Management in Patients With Cardiometabolic Risk. Brunzell, John D.; Davidson, Michael; Furberg, Curt D.; Goldberg, Ronald B.; Howard, Barbara V.; Stein, James H.; Witztum, Joseph L. // Diabetes Care;Apr2008, Vol. 31 Issue 4, p811 

    The article focuses on lipoprotein management in patients with cardiometabolic risk (CMR). It discusses the extent of contribution of lipoproteins to cardiovascular disease (CVD) as well as the factors that should be considered in evaluating and treating patients with lipoprotein abnormalities....

  • Improvement of LDL-C Laboratory Values Achieved by Participation in a Cardiac or Diabetes Disease Management Program. Orr, Patty; Hobgood, Adam; Coberley, Sadie; Roberts, Patricia; Stegall, Gerrye; Coberley, Carter; Pope, James // Disease Management;Dec2006, Vol. 9 Issue 6, p360 

    Poor lipid control is a risk factor for cardiovascular diseases and diabetes complications. Frequently, however, patients with these diseases do not achieve blood lipid levels recommended by current standards of care. A retrospective study of 67,244 members eligible for disease management (DM)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics